Sara L Bissett1, Anna Godi1, Mark Jit2, Simon Beddows3. 1. Virus Reference Department, Public Health England, London, UK. 2. Modelling and Economics Unit, Public Health England, London, UK; Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. 3. Virus Reference Department, Public Health England, London, UK. Electronic address: simon.beddows@phe.gov.uk.
Abstract
BACKGROUND: Human papillomavirus vaccines have demonstrated remarkable efficacy against persistent infection and disease associated with vaccine-incorporated genotypes and a degree of efficacy against some genetically related, non-vaccine-incorporated genotypes. The vaccines differ in the extent of cross-protection against these non-vaccine genotypes. Data supporting the role for neutralizing antibodies as a correlate or surrogate of cross-protection are lacking, as is a robust assessment of the seroconversion rates against these non-vaccine genotypes. METHODS: We performed a systematic review and meta-analysis of available data on vaccine-induced neutralizing antibody seropositivity to non-vaccine incorporated HPV genotypes. RESULTS: Of 304 articles screened, 9 were included in the analysis representing ca. 700 individuals. The pooled estimate for seropositivity against HPV31 for the bivalent vaccine (86%; 95%CI 78-91%) was higher than that for the quadrivalent vaccine (61%; 39-79%; p=0.011). The pooled estimate for seropositivity against HPV45 for the bivalent vaccine (50%; 37-64%) was also higher than that for the quadrivalent vaccine (16%; 6-36%; p=0.007). Seropositivity against HPV33, HPV52 and HPV58 were similar between the vaccines. Mean seropositivity rates across non-vaccine genotypes were positively associated with the corresponding vaccine efficacy data reported from vaccine trials. CONCLUSIONS: These data improve our understanding of vaccine-induced functional antibody specificity against non-vaccine incorporated genotypes and may help to parameterize vaccine-impact models and improve patient management in a post-vaccine setting. Crown
BACKGROUND:Human papillomavirus vaccines have demonstrated remarkable efficacy against persistent infection and disease associated with vaccine-incorporated genotypes and a degree of efficacy against some genetically related, non-vaccine-incorporated genotypes. The vaccines differ in the extent of cross-protection against these non-vaccine genotypes. Data supporting the role for neutralizing antibodies as a correlate or surrogate of cross-protection are lacking, as is a robust assessment of the seroconversion rates against these non-vaccine genotypes. METHODS: We performed a systematic review and meta-analysis of available data on vaccine-induced neutralizing antibody seropositivity to non-vaccine incorporated HPV genotypes. RESULTS: Of 304 articles screened, 9 were included in the analysis representing ca. 700 individuals. The pooled estimate for seropositivity against HPV31 for the bivalent vaccine (86%; 95%CI 78-91%) was higher than that for the quadrivalent vaccine (61%; 39-79%; p=0.011). The pooled estimate for seropositivity against HPV45 for the bivalent vaccine (50%; 37-64%) was also higher than that for the quadrivalent vaccine (16%; 6-36%; p=0.007). Seropositivity against HPV33, HPV52 and HPV58 were similar between the vaccines. Mean seropositivity rates across non-vaccine genotypes were positively associated with the corresponding vaccine efficacy data reported from vaccine trials. CONCLUSIONS: These data improve our understanding of vaccine-induced functional antibody specificity against non-vaccine incorporated genotypes and may help to parameterize vaccine-impact models and improve patient management in a post-vaccine setting. Crown
Authors: Alan A Nguyen; Saddiq B Habiballah; Craig D Platt; Raif S Geha; Janet S Chou; Douglas R McDonald Journal: Clin Immunol Date: 2020-05-11 Impact factor: 3.969
Authors: M Jesus Purriños-Hermida; María Isolina Santiago-Pérez; Mercedes Treviño; Rafaela Dopazo; Angelina Cañizares; Isolina Bonacho; Matilde Trigo; M Eva Fernández; Ana Cid; David Gómez; Patricia Ordóñez; Amparo Coira; M J Armada; Magdalena Porto; Sonia Perez; Alberto Malvar-Pintos Journal: PLoS One Date: 2018-08-03 Impact factor: 3.240
Authors: Ana Paula Costa; Paulo César Giraldo; Ricardo Ney Cobucci; Márcia Lopes Consolaro; Raquel Pantarotto Souza; Luanda Barbara Canário; Paula Renata Machado; Rand Randall Martins; Pedro Vieira Baptista; José Eleutério Jr; Ana Katherine Gonçalves Journal: Asian Pac J Cancer Prev Date: 2020-09-01